Equities research analysts expect that GlycoMimetics, Inc. (NASDAQ:GLYC) will announce earnings of ($0.30) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for GlycoMimetics’ earnings, with estimates ranging from ($0.32) to ($0.27). GlycoMimetics posted earnings of ($0.34) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.8%. The firm is scheduled to report its next earnings report on Friday, November 3rd.
On average, analysts expect that GlycoMimetics will report full-year earnings of ($1.30) per share for the current year, with EPS estimates ranging from ($1.46) to ($1.18). For the next year, analysts anticipate that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($2.10) to $0.31. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow GlycoMimetics.
GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Tuesday, May 2nd. Cowen and Company reiterated a “buy” rating on shares of GlycoMimetics in a report on Tuesday, May 9th. Canaccord Genuity reiterated a “buy” rating and set a $12.00 price objective on shares of GlycoMimetics in a report on Friday, May 19th. ValuEngine upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Jefferies Group LLC reduced their price objective on shares of GlycoMimetics from $16.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $14.20.
GlycoMimetics (GLYC) traded up 3.34% on Friday, reaching $12.07. 360,027 shares of the company traded hands. The stock has a 50-day moving average of $11.56 and a 200 day moving average of $7.90. GlycoMimetics has a 52-week low of $3.82 and a 52-week high of $16.94. The company’s market capitalization is $297.40 million.
WARNING: “Analysts Anticipate GlycoMimetics, Inc. (NASDAQ:GLYC) Will Announce Earnings of -$0.30 Per Share” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/08/08/analysts-anticipate-glycomimetics-inc-nasdaqglyc-will-announce-earnings-of-0-30-per-share.html.
In other news, SVP Helen M. Thackray sold 2,000 shares of GlycoMimetics stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $15.57, for a total transaction of $31,140.00. Following the completion of the transaction, the senior vice president now directly owns 152,615 shares in the company, valued at $2,376,215.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 43.80% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of GLYC. Prentiss Smith & Co. Inc. boosted its position in shares of GlycoMimetics by 42.9% in the second quarter. Prentiss Smith & Co. Inc. now owns 10,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 3,000 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of GlycoMimetics during the fourth quarter worth about $172,000. TD Asset Management Inc. acquired a new position in shares of GlycoMimetics during the second quarter worth about $362,000. Private Capital Advisors Inc. acquired a new position in shares of GlycoMimetics during the second quarter worth about $446,000. Finally, Bank of New York Mellon Corp boosted its position in GlycoMimetics by 159.4% in the second quarter. Bank of New York Mellon Corp now owns 92,911 shares of the biotechnology company’s stock valued at $1,037,000 after buying an additional 57,091 shares during the period. Hedge funds and other institutional investors own 61.80% of the company’s stock.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Get a free copy of the Zacks research report on GlycoMimetics (GLYC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
